GDF 15 - A Novel Biomarker in the Offing for Heart Failure

  • George M
  • Jena A
  • Srivatsan V
  • et al.
94Citations
Citations of this article
103Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND Several diagnostic and prognostic biomarkers are being explored in heart failure. GDF-15 belongs to the transforming growth factor β (TGF-β) cytokine family that is highly up regulated in inflammatory conditions. We undertook this systematic review to summarize the current evidence on the utility of GDF-15 as a biomarker in heart failure. DESIGN AND METHODS Multiple electronic databases for studies that reported the association between GDF- 15 and heart failure were searched using different electronic databases such as MEDLINE, Science Direct, Springer Link, Scopus, Cochrane Reviews, and Google Scholar using pre-defined inclusion- exclusion criteria. RESULTS Twenty one original studies were identified that included data from 20,920 study participants. GDF 15 was found to be a strong prognosticator of all-cause mortality in heart failure patients. Several studies found the benefit of using GDF-15 as a component of a multi-biomarker strategy in prognosticating patients with heart failure. CONCLUSION More studies are warranted to elucidate the molecular pathways involving GDF-15 and to see how knowledge about GDF-15 can be used to make therapeutic decisions in the clinic.

Cite

CITATION STYLE

APA

George, M., Jena, A., Srivatsan, V., Muthukumar, R., & Dhandapani, V. (2016). GDF 15 - A Novel Biomarker in the Offing for Heart Failure. Current Cardiology Reviews, 12(1), 37–46. https://doi.org/10.2174/1573403x12666160111125304

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free